This invention provides a non-aqueous electrolyte magnesium secondary battery comprising a positive electrode, a negative electrode, a separator, and a non-aqueous electrolyte, the non-aqueous electrolyte comprising [N(SO.sub.2CF.sub.3).sub.2].sup.− as an anion, and Mg.sup.2+ and/or an organic onium cation as a cation.

This invention provides a non-aqueous electrolyte magnesium secondary battery comprising a positive electrode, a negative electrode, a separator, and a non-aqueous electrolyte, the non-aqueous electrolyte comprising [N(SO.sub.2CF.sub.3).sub.2].sup.− as an anion, and Mg.sup.2+ and/or an organic onium cation as a cation.

The present invention relates to compounds according to general formula (I) which are analogues of epoxymetabolites produced by cytochrome P450 (CYP) enzymes from omega-3 (n-3) polyunsaturated fatty acids (PUFAs). The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for the treatment or prevention of conditions and diseases associated with inflammation, proliferation, hypertension, coagulation, immune function, pathologic angiogenesis, heart failure and cardiac arrhythmias.

The present invention relates to compounds according to general formula (I) which are analogues of epoxymetabolites produced by cytochrome P450 (CYP) enzymes from omega-3 (n-3) polyunsaturated fatty acids (PUFAs). The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for the treatment or prevention of conditions and diseases associated with inflammation, proliferation, hypertension, coagulation, immune function, pathologic angiogenesis, heart failure and cardiac arrhythmias.

This invention provides a non-aqueous electrolyte magnesium secondary battery comprising a positive electrode, a negative electrode, a separator, and a non-aqueous electrolyte, the non-aqueous electrolyte comprising [N(SO.sub.2CF.sub.3).sub.2].sup.− as an anion, and Mg.sup.2+ and/or an organic onium cation as a cation.

This invention provides a non-aqueous electrolyte magnesium secondary battery comprising a positive electrode, a negative electrode, a separator, and a non-aqueous electrolyte, the non-aqueous electrolyte comprising [N(SO.sub.2CF.sub.3).sub.2].sup.− as an anion, and Mg.sup.2+ and/or an organic onium cation as a cation.

The present disclosure generally relates to novel compounds as a fatty acid synthase inhibitor useful for the treatment of infection diseases, cancers, or metabolic diseases that malfunction of fatty acid synthase is involved. In particular this present invention directs to malonyl-coenzyme A (CoA) mimetics and methods of use thereof. The invention described herein also pertains to pharmaceutical compositions and methods for treating diseases in mammals using compounds disclosed herein.

A maleamic acid monomer, and a preparation method and a use of the maleamic acid monomer. The structural formula of the monomer is as follows: ##STR00001##
formula (1), wherein, R is selected from ##STR00002##
The maleamic acid monomer provided in the present invention may be used as a comonomer to prepare temperature-tolerant and calcium salt-tolerant polymers.

A maleamic acid monomer, and a preparation method and a use of the maleamic acid monomer. The structural formula of the monomer is as follows: ##STR00001##
formula (1), wherein, R is selected from ##STR00002##
The maleamic acid monomer provided in the present invention may be used as a comonomer to prepare temperature-tolerant and calcium salt-tolerant polymers.

A N-acylated taurine composition comprising: (a) a first N-acylated taurine compound of the formula (IA) or a salt thereof:

##STR00001## and (b) a second N-acylated taurine compound of the formula (IB) or a salt thereof:

##STR00002## wherein R.sup.1a and R.sup.2a are C.sub.1-4 alkyl, wherein R.sup.1a and R.sup.2a are the same; R.sup.3 is C.sub.1-6 alkyl, C.sub.2-6 alkenyl or C.sub.1-6 alkyl substituted with an aryl group; and R.sup.4 is C.sub.4-25 alkyl or C.sub.4-25 alkenyl, wherein the C.sub.4-25 alkyl or C.sub.4-25 alkenyl is optionally substituted by hydroxy.